Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma

Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma - Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004374

Enrollment

100

Registered

2010-10-13

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically confirmed metastatic RCC with a component of clear cell histology. Presence of measurable disease; that is, at least 1 metastatic tumor mass that can be accurately measured in at least 1 dimension over 10 mm with conventional radiological modalities, such as computed tomography and magnetic resonance imaging. Age of over 20 years. ECOG performance status of 0 or 1. Life expectancy of over 12 weeks

Exclusion criteria

Exclusion criteria: Prior use of sunitinib Seizure disorder, evidence of brain metastases, spinal cord compression or carcinomatous meningitis. Active bacterial, fungal or viral infection. History of malignancy other than RCC except for those treated with curative intent with no evidence of disease for at least 2 years. Other severe acute or chronic medical condition.

Design outcomes

Primary

Measure	Time frame
&#61656;Before and during treatment with sunitinib, measure serum levels of several molecules (E-cadherin, N-cadherin, fibronectin, MMP-2, MMP-3, MMP-9, MT-MMP-1, TIMP-1, TIMP-2, clusterin, bFGF, uPA and uPAR), which have been shown to be regulated by activated p44/42 MAPK and Akt and to be involved in the acquisition of an EMT phenotype in our preliminary experiments, in patients with metastatic RCC by sandwich enzyme-linked immunosorbent assay (ELISA) kits.	—

Measure

Time frame

&#61656;Before and during treatment with sunitinib, measure serum levels of several molecules (E-cadherin, N-cadherin, fibronectin, MMP-2, MMP-3, MMP-9, MT-MMP-1, TIMP-1, TIMP-2, clusterin, bFGF, uPA and uPAR), which have been shown to be regulated by activated p44/42 MAPK and Akt and to be involved in the acquisition of an EMT phenotype in our preliminary experiments, in patients with metastatic RCC by sandwich enzyme-linked immunosorbent assay (ELISA) kits.

—

Countries

Japan

Outcome results